MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. By continuing to use our service, you agree to our use of cookies. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. We also use them to. We also use them to share usage information with our partners. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. " The 12-month stock price forecast is $18. com uses cookies on this site. This suggests a possible upside of 2,471. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Stockhouse. 617-356-1009. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. European Headquarters. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. Stockhouse. 2% per year. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. stock price gained 1. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. For investor inquiries: Leah Gibson. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). 1300 (+9. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 74M. We also use them to share. com uses cookies on this site. Forecast to breakeven in 2024 Jul 15. Cookies are used to offer you a better browsing experience and to analyze our traffic. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies reduces R&D head count to compensate for sales setback. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Phone Number (514) 336-7800. Theratechnologies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 36 morning pop. Biopharmaceutical company Theratechnologies Inc. com uses cookies on this site. 4% annually. 11/05/2020 4:15:02 PM. 23) diluted earnings per. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. October 13, 2022 07:30 ET | Source: Theratechnologies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. By continuing to use our service, you agree to our use of cookies. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. View real-time stock prices and stock quotes for a full financial overview. ("Theratechnologies" or the "Company"). MONTREAL, Jan. MONTREAL, Feb. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. T. Investor inquiries: Elif McDonald. 51 to 200 Employees. com. Denis Boucher. (Image via Theralase Technologies Inc. This news release constitutes a “designated news release” for the purposes of the Company’s. By continuing to use our service, you agree to our use of cookies. Company Type For Profit. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. Q3 2023 consolidated revenue of $20. Senior Director, Communications & Corporate Affairs. 00. com uses cookies on this site. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 1. 's motion for leave to commence. VANCOUVER, British Columbia, Nov. 2 million. 1-438. - Q3 2022 Consolidated Revenue Growth of 17% to $20. 63. A live webcast of Dr. MONTREAL, Oct. stock price gained 6. Further. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. 1M. By continuing to use our service, you agree to our use of cookies. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. com. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. About Us | Theratechnologies Inc. 60%. . (TH. Find more information. . THERATECHNOLOGIES INC. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. When this page refreshes you will be logged in with the new address. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Montréal, Québec, Canada . Contact Email communications@theratech. Herein, we report. 69 to $1. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. MONTREAL, Sept. Find the latest Theratechnologies Inc. (882) posted 3 minutes ago. MONTREAL, Feb. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. . MONTREAL, Aug. Currency in USD Follow 2W 10W 9M 1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies develops and commercializes innovative therapies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. ir@theratech. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. com uses cookies on this site. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. Theratechnologies, Inc. T. Phone Number 15143319691. T. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Nov. Stockhouse. 9 million and US. During the last trading day the stock fluctuated 4. The abstract and poster can be found on Theratechnologies’ website. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. THERATECHNOLOGIES INC. 67, which is an increase of 1,144. 51 S1. com uses cookies on this site. . Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. com uses cookies on this site. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. TH | September 26, 2023. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. RESSOURCES. Message Board Total Posts: 4. Market Cap. com uses cookies on this site. MONTREAL, Oct. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. 33. Data presented at AMCP Nexus 2023. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. 8. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. (882) posted 3 minutes ago. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. 00. Wainwright NASH Investor Conference. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. Investor Relations. B2Gold Declares Fourth Quarter 2023 Dividend. NEW YORK, Dec. com uses cookies on this site. About Theratechnologies. com uses cookies on this site. -based clinical sites participating in the conduct of the Phase. C. By continuing to use our service, you agree to our use of cookies. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. com uses cookies on this site. m. Cookies are used to offer you a better browsing experience and to. 6. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. By continuing to use our service, you agree to our use of cookies. We also use them to share usage. $30. MONTREAL, Nov. Marsolais’ presentation will be available through. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. By continuing to use our. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. For investor inquiries: Leah Gibson. Heures de négociation. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Provides Details About R&D Day Webcast. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. About SORT1+ Technology™ and TH1902. Clinical-stage pharmaceutical company Theralase Technologies Inc. Stockhouse. It is the Company’s proprietary. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Saint-Laurent, Canada. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Focused on small-cap companies and sectors. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. Theratechnologies has generated ($1. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. One reason for that is that this tier does not include penny stocks. com uses cookies on this site. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . NCU. Stockhouse. A high-level overview of Theratechnologies Inc. Theratechnologies layoffs. TH 48% v4,15M c1. THTX earnings call for the period ending February 29, 2020. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. Theratechnologies to Announce Financial Results for Its First Quarter 2022. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. Watch list NEW Set a price target alert After Hours Last. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. We also use them to share usage. 2. Theratechnologies inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. US Headquarters. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. MONTREAL, Nov. A high-level overview of Theratechnologies Inc. (THTX) NasdaqCM - NasdaqCM Real Time Price. Stockhouse. We also use them to share usage information with our partners. Cookies are used to offer you a better browsing experience and to analyze our traffic. Stockhouse. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. 72%. T. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. . (TH. This news release constitutes a “designated news release” for the purposes of the Company’s. Stockhouse. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - Q3 2022 North American Revenue Growth of 19%. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. Stockhouse. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. 00 in the next twelve months. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. Q4 2022 consolidated revenue growth of 14. 39 50-Day Range $0. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. 2% to $21. OTCQX – this is the premium tier of OTC stocks. MONTREAL, Oct. GlobeNewswire. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. 9% more than in 2021. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. MONTREAL, Jan. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Theratechnologies had a negative net margin of 36. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. Theratechnologies, Inc. Stockhouse. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. We also use them to share usage. European Headquarters. com uses cookies on this site. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. S. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. MONTREAL, Oct. Further. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. MONTREAL, Feb. FY2023 revenue guidance range set between $90 million and $95 million. TH | February 28, 2023. MONTREAL, Dec. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies had a negative net margin of 36. com. MONTREAL, Oct. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. 00%. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Website. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. lgibson. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. Montreal-based biopharmaceutical company Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. View real-time stock prices and stock quotes for a full financial overview. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. TH | February 28, 2023. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. Stockhouse. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Their THTX share price targets range from $36. Track Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. L. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Stockhouse. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 74M. com uses cookies on this site. com. Stockhouse. We currently market prescription products for people with HIV in the United States. 9 million, adjusted EBITDA of $2. Theratechnologies Inc. Theratechnologies Inc. View recently published Stock News reports from independent reports and journalists. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. 26 +15. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. 89 $2. We also use them to share usage. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. znewcar1. 35 as of 10:41 a. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. com uses cookies on this site. TH | September 5, 2023. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share usage. (“Theratechnologies”) with the Securities and Exchange Commission (the.